TEM8

Demande de produit

TEM8Contexte de la molécule

This gene encodes a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. The encoded protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants that encode different protein isoforms have been described. [provided by RefSeq, Oct 2008]

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Riliprubart	BIVV-020; SAR-445088; TNT-020	Phase 3 Clinical	True North Therapeutics	Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic; Polyradiculoneuropathy; Rejection of organ transplantation; Anemia, Hemolytic, Autoimmune; Nervous System Diseases	Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical)		Phase 3 Clinical	Boya Bio-Pharmaceutical Group Co Ltd	Angioedemas, Hereditary	Details
Complement-C1 inhibitor protein (Octapharma)		Phase 2 Clinical	Octapharma	Angioedemas, Hereditary	Details
DNTH-103	DNTH-103; DNTH103	Phase 2 Clinical	Dianthus Therapeutics Inc	Myasthenia Gravis; Autoimmune Diseases	Details
C1 esterase inhibitor (Chengdu Institute of Biological Products)		Phase 1 Clinical	Chengdu Institute Of Biological Products Co Ltd	Angioedemas, Hereditary	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Conestat alfa	rhC1-INH	Approved	Pharming Group Nv	Rhucin, Esterasine, Ruconest	EU	Angioedemas, Hereditary	Pharming Group Nv	2010-10-28	Rejection of renal transplantation; Renal Insufficiency; Genetic Diseases, Inborn; Rejection of organ transplantation; Coronavirus Infections; Angioedema; Angioedemas, Hereditary; Non-ST Elevated Myocardial Infarction	Details
Sutimlimab	BIVV-009; TNT-009	Approved	True North Therapeutics	ENJAYMO	United States	Anemia, Hemolytic, Autoimmune	Bioverativ Therapeutics Inc	2022-02-04	Hemolysis; Purpura, Thrombocytopenic, Idiopathic; Anemia, Hemolytic, Autoimmune; Pemphigoid, Bullous; Kidney Failure, Chronic	Details
Complement C1 inhibitor protein (Shire ViroPharma)	C1 INH-nf; C1-INH; SHP-616	Approved	Sanquin Plasma Products Bv	Cinryze, Cetor	United States	Angioedemas, Hereditary	null	2008-10-10	Brain Injuries, Traumatic; Rejection of organ transplantation; Angioedemas, Hereditary	Details
C1 esterase inhibitor (Human, CSL Behring)	BI-3.012; CSL-830; CSL-842; CE-1145	Approved	Csl Behring Llc	Berinert, Haegarda, Berinert 2000	Japan	Angioedemas, Hereditary	Csl Behring Llc	1990-06-29	Hereditary Angioedema Types I and II; Angioedemas, Hereditary	Details